Uncategorized
UK authority backs down in Novartis eye drug dispute
LONDON (Reuters) - A regional British health authority said on Wednesday it had decided to stop using
the cancer drug Avastin as a cheap alternative to eye medicine Lucentis following a legal challenge from Novartis,
which sells Lucentis in Europe.